---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291416761.md"
description: "Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes.."
datetime: "2026-07-01T12:00:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291416761.md)
  - [en](https://longbridge.com/en/news/291416761.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291416761.md)
generator: "portal-rs"
---

# 

Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes..

### Related Stocks

- [CANF.US](https://longbridge.com/en/quote/CANF.US.md)

## Related News & Research

- [Can-Fite plans Phase IIb trial of namodenoson plus gemcitabine in advanced pancreatic cancer](https://longbridge.com/en/news/296095129.md)
- [Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance](https://longbridge.com/en/news/295654944.md)
- [Is Wall Street Bullish or Bearish on Cadence Design Stock?](https://longbridge.com/en/news/296378129.md)
- [Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics](https://longbridge.com/en/news/296641838.md)
- [Aflac (NYSE:AFL) Major Shareholder Post Holdings Co. Ltd. Japan Sells 12,700 Shares of Stock](https://longbridge.com/en/news/296680553.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**